Comparison of stereotactic body radiation therapy with and without sorafenib as treatment for hepatocellular carcinoma with portal vein tumor thrombosis

doi:10.1097/MD.0000000000019660

CNU IR > College of Smart Living > Dept. of Hospital and Health (including master's program) > Periodical Articles > Item 310902800/34117

Please use this identifier to cite or link to this item: https://ir.cnu.edu.tw/handle/310902800/34117

Title:	Comparison of stereotactic body radiation therapy with and without sorafenib as treatment for hepatocellular carcinoma with portal vein tumor thrombosis
Authors:	Que, Jenny Wu, Hung-Chang Lin, Chia-Hui Huang, Chung-, I Li, Li-Ching Ho, Chung-Han
Contributors:	Chi Mei Med Ctr, Dept Radiat Oncol Chia Nan Univ Pharm & Sci, Dept Hosp & Hlth Care Adm E Da Canc Hosp, Dept Internal Med, Div Hematol Oncol E Da Canc Hosp, Dept Radiat Oncol Chi Mei Med Ctr, Dept Med Res
Keywords:	portal vein tumor thrombosis sorafenib stereotactic body radiation therapy
Date:	2020
Issue Date:	2022-11-18 11:24:35 (UTC+8)
Publisher:	Lippincott Williams & Wilkins
Abstract:	Stereotactic body radiation therapy (SBRT) has emerged as a treatment option for unresectable hepatocellular carcinoma (HCC) patients. However, the treatment outcomes for patients with portal vein tumor thrombosis (PVTT) remain poor. In this study, we evaluate the efficacy of SBRT with and or without sorafenib for advanced HCC with PVTT. Fifty four HCC patients with PVTT treated with SBRT using the Cyberknife system was retrospectively analyzed between January 2009 and June 2016. Of these, sorafenib combined with SBRT was administered to 18 patients and SBRT alone was administered to 36 patients. SBRT was designed to target the liver tumor and tumor thrombosis, with a radiation dose of 36 to 45 Gy (median 40 Gy) given in 3 to 5 fractions. The mean follow-up period for SBRT with sorafenib and SBRT alone was 13.22 +/- 10.07 months and 15.33 +/- 22.01 months, respectively. The response rate was comparable in both groups. Complete response and partial response rates were 77.77% for SBRT with sorafenib and 75.00% without sorafenib (P = .43). The median progression-free survival rate was 6 months (2-11 months) versus 3 months (2-5.6 months) (P = .24) and the 1- and 2-year progression-free survival rates were 25.7% and 15.2% versus 11.1% and 8.3% (P = .1225). The median, 1- and 2-year overall survival rates (OSR) were 12.5 months, 55.6% and 17.7% versus 7 months (5-13.5 months), 33.3% and 11.1% (P = .28), for SBRT with sorafenib versus SBRT alone groups, respectively. The result of our study shows that SBRT with sorafenib administered group resulted in a higher median, progression-free, and OSR for HCC patients with PVTT. However, the trends did not attain statistical significance. A large-scale randomized study is needed to assess the benefits of SBRT with sorafenib administration for patient with PVTT.
Relation:	Medicine, v.99, n.13, pp.9
Appears in Collections:	[Dept. of Hospital and Health (including master's program)] Periodical Articles

Files in This Item:

File	Description	Size	Format
index.html		0Kb	HTML	564	View/Open

Loading...